Earnings call transcript: Neuland Laboratories posts softer Q2 2026 results

Neuland Laboratories disclosed weaker second-quarter earnings for FY 2027 in its earnings call transcript, with total income falling 11.4% year-over-year to INR 457.2 crores. The company attributed the decline to higher costs, a less favorable product mix, and uneven customer shipments. Despite the weaker quarter, management noted strong demand for upcoming projects and progress in peptides, a key focus area for the company.

Revenue and profit both declined compared to the previous year. The business remains in an inflection period as contract development and manufacturing organization (CDMO) services become a larger part of the company's operations. Neuland's main forward-looking themes include strong RFP activity, a growing Phase III pipeline, and the company's long-term growth strategy in peptides.